Dong-A Socio Holdings
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Dong-A Socio Holdings is a Korean holding company, a parent entity that manages a group of operating subsidiaries, whose businesses span over-the-counter medicines, biosimilar drug manufacturing, logistics, glass packaging, bottled water, and IT services.
Its products and services reach consumers, healthcare providers, and industrial customers across these distinct segments. Listed on KOSPI, Korea's main stock exchange, the company operates six separate reporting divisions, each run independently with its own technology and marketing approach.
Summary is AI-generated and may contain errors · figures from DART filings
As a holding company, it does not operate businesses directly but earns income through its subsidiaries, making its financial performance a consolidated picture of multiple distinct industries.
Dong-A Socio Holdings in five facts
What does Dong-A Socio Holdings do?
Dong-A Socio Holdings is a Korean holding company, a parent entity that manages a group of operating subsidiaries, whose businesses span over-the-counter medicines, biosimilar drug manufacturing, logistics, glass packaging, bottled water, and IT services.
Where is Dong-A Socio Holdings listed and in which sector?
Dong-A Socio Holdings (Korean name: 동아제약) trades under KRX code 000640 on KOSPI, the main board of the Korea Exchange. It is classified in the Financials sector, Diversified Financials.
How large is Dong-A Socio Holdings?
Its market capitalisation was US$466.5M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Dong-A Socio Holdings's latest annual revenue and operating profit?
For fiscal year 2025, Dong-A Socio Holdings reported revenue of US$1.1B, operating profit of US$73.8M and net income of US$69M, per its annual report on DART (data retrieved from DART on 2026-09-05). Revenue was up 7.2% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-05
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Supply contract signed (subsidiary)
Dong-A Socio Holdings disclosed a subsidiary's supply contract, worth US$10M, about 13% of the subsidiary's recent annual revenue, running through Jun 2027.
Supply contract · Oct 16 - Change in shares held by the largest shareholderOct 8
- Report on securities held by executives/major shareholdersOct 8
- Report on securities held by executives/major shareholdersOct 8
- Report on securities held by executives/major shareholdersOct 8
- Report on securities held by executives/major shareholdersOct 8
- Report on securities held by executives/major shareholdersOct 8
- Report on securities held by executives/major shareholdersOct 8
- Report on securities held by executives/major shareholdersOct 8
- Report on securities held by executives/major shareholdersOct 8
- Report on securities held by executives/major shareholdersOct 8
- Report on securities held by executives/major shareholdersOct 8
- Report on securities held by executives/major shareholdersOct 8
- Report on securities held by executives/major shareholdersOct 8
- DisclosureOct 2
- DisclosureOct 2
- Completion report on merger, etc. (merger)
Dong-A Pharmaceutical Co., Ltd. (formerly Dong-A Socio Holdings Co., Ltd.) completed a small-scale merger absorbing the extinguished company, also named Dong-A Pharmaceutical Co., Ltd. prior to the merger, effective October 1, 2026, issuing no new shares; 103 shareholders holding 6,166 shares (0.09% of outstanding shares) had filed notices of dissent, and no creditor objections were received.
M&A · Oct 2 - Report on large shareholdings (5% rule) (abbreviated)Oct 2
- [Amended] Supply contract signed (subsidiary)
Dong-A Socio Holdings amended an April 20, 2026 disclosure to extend the non-disclosure deadline to October 7, 2029 and to correct the subsidiary's name, for its subsidiary's US$5.56M pharmaceutical contract manufacturing agreement.
Supply contract · Sep 30 · 2 versions - Results of extraordinary shareholders' meetingSep 22
- Supply contract signed (subsidiary)
Dong-A Socio Holdings disclosed a subsidiary's supply contract, worth US$66.2M, about 27.54% of the subsidiary's recent annual revenue, running through Nov 2027.
Supply contract · Sep 18 - Proxy solicitation reference documentSep 7
- Notice of general shareholders' meetingSep 7
- [Amended] Decision to guarantee a third party's debtSep 4
- Change in shares held by the largest shareholderSep 2
- Report on securities held by executives/major shareholdersSep 2
- Report on large shareholdings (5% rule) (standard)Sep 2
- Supply contract signed (subsidiary)
Dong-A Socio Holdings disclosed a subsidiary's supply contract, worth US$9.89M, about 13.2% of the subsidiary's recent annual revenue, running through Jun 2027.
Supply contract · Aug 28 - Operating results (consolidated) (preliminary) (fair disclosure)
Dong-A Socio Holdings filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$282M (+18.88% year on year) and operating profit of US$26.6M (+38.35% year on year).
Earnings · Jul 27 - [Attachment amended] Material event report (merger)M&A · Jul 27
- Material event report (merger)
Dong-A Socio Holdings decided on 2026-07-23 to absorb its wholly owned (100%) subsidiary Dong-A Pharm Co., Ltd. in a small-scale, no-new-shares merger effective 2026-10-01, to internalize Dong-A Pharm's consumer-healthcare competitiveness and stable cash flow as an operating holding company; because no merger shares are issued, no appraisal rights apply and there is no change in the largest shareholder.
M&A · Jul 23 - Cash/in-kind dividend decision
Dong-A Socio Holdings declared a cash dividend of US$0.47 per share, equal to about 0.9% of the recent share price.
Dividend · Jul 16 - [Amended] Supply contract signed (subsidiary)
Dong-A Socio Holdings updated a subsidiary's previously disclosed supply contract, now worth US$5.87M, about 15.02% of the subsidiary's recent annual revenue, running through Mar 2027.
Supply contract · Jul 10 - Operating results (consolidated) (preliminary) (fair disclosure)
Dong-A Socio Holdings filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$238M (+6.88% year on year) and operating profit of US$13M (−5.96% year on year).
Earnings · Apr 27 - [Amended] Cash/in-kind dividend decision (subsidiary)Dividend · Apr 21 · 2 versions
- Supply contract signed (subsidiary)
Dong-A Socio Holdings disclosed a subsidiary's supply contract, worth US$59.8M, about 32.8% of the subsidiary's recent annual revenue, running through Nov 2027.
Supply contract · Mar 16 - Supply contract signed (subsidiary)
Dong-A Socio Holdings disclosed a subsidiary's supply contract, worth US$4.42M, about 11.28% of the subsidiary's recent annual revenue, running through Mar 2027.
Supply contract · Mar 16 - Supply contract signed (subsidiary)Supply contract · Mar 10
- Stock dividend decisionDividend · Feb 25
- Cash/in-kind dividend decision
Dong-A Socio Holdings declared a cash dividend of US$0.69 per share.
Dividend · Feb 25